Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-993X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study ; volume:16 ; number:1 ; day:18 ; month:8 ; year:2015 ; pages:1-11 ; date:12.2015
Respiratory research ; 16, Heft 1 (18.8.2015), 1-11, 12.2015
- Urheber
-
O’Byrne, Paul M.
- Beteiligte Personen und Organisationen
-
D’Urzo, Tony
Beck, Ekkehard
Fležar, Matjaž
Gahlemann, Martina
Hart, Lorna
Blahova, Zuzana
Toorawa, Robert
Beeh, Kai-Michael
SpringerLink (Online service)
- DOI
-
10.1186/s12931-015-0249-8
- URN
-
urn:nbn:de:1111-201611086378
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- O’Byrne, Paul M.
- D’Urzo, Tony
- Beck, Ekkehard
- Fležar, Matjaž
- Gahlemann, Martina
- Hart, Lorna
- Blahova, Zuzana
- Toorawa, Robert
- Beeh, Kai-Michael
- SpringerLink (Online service)
Ähnliche Objekte (12)
A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis
First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
Correction: First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study
Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study
Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study
A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis
First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
Correction: First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study
Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study
Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study
A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis
First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
Correction: First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study
Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study